RecruitingPhase 4NCT04575844

Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome


Sponsor

University of Virginia

Enrollment

80 participants

Start Date

Nov 1, 2020

Study Type

INTERVENTIONAL

Conditions

Summary

The primary objective of this study is to examine whether exercise training alone, liraglutide treatment alone or exercise training plus liraglutide treatment increases cardiac and skeletal muscle microvascular blood volume, improves vascular function of the conduit vessels, and enhances insulin's metabolic action in humans with Metabolic Syndrome. Subjects will be randomized to one of the 4 groups: control, exercise training, liraglutide treatment, and exercise + liraglutide. They will be studied at the baseline and then after 24 weeks of intervention.


Eligibility

Min Age: 21 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Exercise training, a drug called Liraglutide, and others for people with metabolic syndrome. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLiraglutide

24 weeks of Liraglutide

OTHERExercise training

24 weeks of Exercise training

DRUGLiraglutide + Exercise training

24 weeks of Liraglutide + Exercise training


Locations(1)

University of Virginia

Charlottesville, Virginia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04575844


Related Trials